Elanco Animal Health SEC Filings

Elanco Animal Health executive Robert M. VanHimbergen, EVP and CFO, reported a small compensation-related equity transaction. On 01/09/2026 he acquired 8.1121 deferred stock units at a reference price of $23.47 per unit, as disclosed on a Form 4.

Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and the units settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan. After this transaction, he beneficially owns 8.1121 deferred stock units directly.

Elanco Animal Health Inc. CEO Jeffrey N. Simmons, who also serves as president and director, reported an acquisition of deferred stock units under a company plan. On January 9, 2026, he was credited with 117.9906 deferred stock units at a reference price of $23.47 per unit, bringing his total holdings to 18,845.5217 deferred stock units.

Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units are designed to settle in cash or shares after employment ends or in a specified future year, in line with the company’s Executive Deferral and Stock Match Plan.

Elanco Animal Health Incorporated filed a report stating that on January 13, 2026, it will present at the 44th Annual J.P. Morgan Healthcare Conference. The company has prepared an investor presentation for this event, which is included as Exhibit 99.1. This presentation is being made available as supplemental information for investors and analysts.

The disclosure is furnished under a provision that means it is not considered “filed” for liability purposes under the Securities Exchange Act and will only be incorporated into other documents if expressly stated. No financial results, transactions, or strategic changes are described in this report beyond the announcement of the conference presentation.

Elanco Animal Health director defers fees into stock units. Director Kapila K. Anand converted a portion of her cash director fees into deferred stock units under Elanco's Directors' Deferral Plan on December 31, 2025. She received 381.1312 Deferred Stock Units, each economically equivalent to one share of Elanco common stock, based on the closing share price of $22.63 on the grant date. Following this transaction, she held a total of 8,894.7414 deferred stock units, which will be settled in Elanco common stock when she separates from the Board of Directors.

Elanco Animal Health Inc. insider Jeffrey N. Simmons, the company’s President, CEO and Director, reported an acquisition of derivative securities in the form of deferred stock units on 12/26/2025. The filing shows he acquired 122.5327 deferred stock units tied to Elanco common stock at a derivative price of $22.6 per unit. Following this transaction, he beneficially owns 18,727.5311 deferred stock units directly.

Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units are scheduled to settle in cash or shares of Elanco common stock after termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.

Elanco Animal Health executive reports deferred stock unit grant. On 12/26/2025, an officer of Elanco Animal Health Inc. acquired 62.5938 deferred stock units under the company’s Executive Deferral and Stock Match Plan. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. Following this transaction, the reporting person beneficially owned 7,420.0759 deferred stock units, which will settle in cash or shares after employment ends or in a specified future year. The officer’s title is Executive Vice President U.S. Pet Health and Global Digital Transformation.

Elanco Animal Health Inc director reports charitable stock gift. Director R. David Hoover reported a transaction dated 12/19/2025 involving Elanco common stock. The filing shows that a revocable trust associated with him disposed of 60,000 shares as a gift to a charitable trust at a reported price of $0 per share.

After this gift, he is shown as beneficially owning 150,000 shares indirectly through a revocable trust, 106,773 shares directly, and 15,920 shares indirectly through the Suzanne A. Hoover Revocable Trust. This reflects a shift in how part of his holdings are allocated, with shares redirected to charitable purposes while maintaining substantial ownership interests.

Elanco Animal Health Inc. director Lawrence Kurzius reported an open-market purchase of company stock. On 12/12/2025, he bought 10,000 shares of Elanco common stock at a price of $21.3 per share. Following this transaction, his directly held beneficial ownership increased to 131,773 shares of Elanco common stock. The filing indicates that it was submitted for one reporting person, reflecting Kurzius’s role as a director of the company.

Elanco Animal Health Inc. officer Rajeev A. Modi reported acquiring additional deferred stock units tied to the company’s common stock. On 12/12/2025, he acquired 66.4453 deferred stock units at a price of $21.29 per unit, increasing his directly held deferred stock units to 7,357.4821.

Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, with settlement following termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.